Dr. Ashani T. Weeraratna on Aging and its Effects on How Melanoma Progresses and is Treated
Ashani T. Weeraratna, PhD, discusses the similarities in treatment between younger and older patients with melanoma. She says this lack of differentiation between treatment regimens could pose a problem in the future. One such issue is that older patients tend to react less well to treatments like vemurafenib.
Ashani T. Weeraratna, PhD, associate professor, Tumor Microenvironment and Metastasis Program, The Wistar Institute, discusses the similarities in treatment between younger and older patients with melanoma. She says this lack of differentiation between treatment regimens could pose a problem in the future. One such issue is that older patients tend to react less well to treatments like vemurafenib.
Weeraratna says in order to better treat older patients with melanoma, medical professional should not resort to dose lowering. She also adds that finding reliable molecular targets in older patients.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
